Independent pharmacies are bound by PSAO contracts they never see, negotiated by wholesaler-owned intermediaries, and auto-accepted via fax if not rejected within two weeks

Independent pharmacies cannot negotiate directly with PBMs for network inclusion and reimbursement rates. Instead, they join Pharmacy Services Administrative Organizations (PSAOs), which negotiate PBM contracts on behalf of groups of pharmacies. The five largest PSAOs are now owned by pharmaceutical wholesalers -- the same companies that sell the pharmacies their drug inventory. After signing a PSAO agreement, the pharmacy is obligated to contracts that the PSAO signs on its behalf, but the pharmacy often cannot see the terms of those contracts or even know they exist. Reimbursement rates, GER benchmarks, audit provisions, and network requirements are all set in contracts the pharmacy owner has never read. The auto-acceptance mechanism is particularly predatory. PBMs send contract amendments to pharmacies via fax. If the pharmacy does not respond within a specified window -- typically one to two weeks -- the contract is deemed accepted. Since contracts arrive by fax, they can be lost, buried in junk faxes, or arrive when the pharmacist is focused on filling 300 prescriptions per day. A missed fax can bind the pharmacy to below-cost reimbursement rates for an entire contract year. The pharmacy owner discovers the new terms only when reimbursement checks start arriving smaller than expected, by which point there is no mechanism to renegotiate. This is not a hypothetical edge case -- pharmacy advocacy groups report it as a widespread, systemic practice. The structural root cause is market concentration and vertical integration. The three largest PBMs control 80% of the market, so they set terms unilaterally. PSAOs were originally created to give independent pharmacies collective bargaining power, but wholesaler acquisition of PSAOs converted them from pharmacy advocates into supply-chain intermediaries with divided loyalties. The wholesaler-owned PSAO has financial incentives to maintain its relationship with PBMs (which drive prescription volume) even at the expense of the pharmacies it ostensibly represents. CMS proposed changes to Part D contracting rules in 2025 that would address some of these issues, but PBMs lobbied aggressively against them, and pharmacies and PBMs remain fundamentally at odds over whether pharmacies should have any meaningful say in the terms that govern their reimbursement.